FT-207 (NSC 148958) , ≥98%(HPLC) , 17902-23-7
Synonym(s):
5-Fluoro-1-(tetrahydro-2-furyl)uracil;Ftorafur;Tegafur
CAS NO.：17902-23-7
Empirical Formula: C8H9FN2O3
Molecular Weight: 200.17
MDL number: MFCD00012351
EINECS: 241-846-2
| Pack Size | Price | Stock | Quantity |
| 5G | RMB52.00 | In Stock |
|
| 25G | RMB126.40 | In Stock |
|
| 100G | RMB488.80 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 171-173 °C(lit.) |
| Density | 1.3222 (estimate) |
| storage temp. | room temp |
| solubility | DMSO: >50mg/mL |
| form | Very Fine Crystalline Powder |
| pka | 7.63±0.10(Predicted) |
| color | white to off-white |
| Merck | 14,9112 |
| InChIKey | WFWLQNSHRPWKFK-UHFFFAOYSA-N |
Description and Uses
Tegafur is an orally bioavailable prodrug form of 5-fluorouracil (5-FU; ). It is converted to 5-FU in vivo enzymatically or by cytochrome P450 oxidation. Tegafur inhibits proliferation of HT-29, BxPC-3, and Panc02 cells (IC50s = 201, 172, and 179 μM, respectively). It also reduces tumor growth in an HT-27 colon carcinoma mouse xenograft model when administered at a dose of 50 mg/kg and in a 4-1ST gastric carcinoma mouse xenograft model when used in combination with uracil. Formulations containing tegafur, in combination with uracil, have been used in the treatment of cancer.
Isotope labelled Tegafur (T013900), used as an antineoplastic.
Safety
| Symbol(GHS) |  GHS06 |
| Signal word | Danger |
| Hazard statements | H301+H311+H331 |
| Precautionary statements | P261-P264-P280-P301+P310-P302+P352+P312-P304+P340+P311 |
| Hazard Codes | T |
| Risk Statements | 23/24/25 |
| Safety Statements | 22-36/37/39-45 |
| RIDADR | UN 2811 6.1/PG 2 |
| WGK Germany | 3 |
| RTECS | YR0450000 |
| HazardClass | 6.1 |
| PackingGroup | II |
| HS Code | 29349990 |
| Toxicity | LD50 in mice (mg/kg): 900 orally (3 days) (Yasumoto); 750 i.p. (FR 1574684), also reported as 1150 i.p. (Smart) |
